India Cracks Down on 90% of High-Risk Pharma Plants, Regulator Reports

The Central Drugs Standard Control Organisation (CDSCO) inspected hundreds of high-risk pharmaceutical facilities across the country and took enforcement action against roughly nine out of ten, the regulator reported.

The actions included issuing show-cause notices, suspending or canceling manufacturing licenses, and ordering product recalls, according to the CDSCO's latest compliance report.

The crackdown is part of a broader effort to improve drug quality and safety standards after a series of contamination incidents and export bans on Indian-made pharmaceuticals in recent years.

The regulator said it prioritized inspections based on risk factors such as past compliance records, product types, and market reach, targeting facilities that posed the highest potential threat to public health.

CDSCO officials stated that the intensified scrutiny would continue, with unannounced inspections and stricter penalties for violations, to ensure sustained compliance across the pharmaceutical sector.